Results 121 to 130 of about 6,680,139 (200)

A chikungunya virus-like particle vaccine reduces chikungunya disease in cynomolgus macaques and protection is mediated by antibody transferred from vaccinated humans. [PDF]

NPJ Vaccines
Coffey LL, Olstad KJ, Reader JR, Ardeshir A, Weiss CM, Watanabe JK, Usachenko JL, Yee J, Singapuri A, Ma ZM, Mackiewicz A, Sammak R, Stuart J, Immareddy R, Anantha R, Warfield KL, Manayani D, Alexander J, Smith J, Vang L, Cirimotich CM, O'Connor C, Guenther B, Ho N, Morello CS, Mendy J, Richardson JS, Van Rompay KKA.   +27 more
europepmc   +1 more source

Impact of Host Cell DNA and Chromatin on Virus-like Particle Analysis by Light Scattering in Asymmetrical Flow Field-flow Fractionation. [PDF]

J Sep Sci
Bacher J, Jakob LA, Mesurado T, Lali N, Zollner A, Jungbauer A, Pereira Aguilar P.   +6 more
europepmc   +1 more source

A new antiserum for the detection of plum bark necrosis stem pitting-associated virus by mean of ELISA

, 2006
POTERE O, BOSCIA D, CASTELLANO M. A, SAVINO, Vito Nicola   +3 more
core  

Safety and Efficacy of Plant-Produced Trivalent Virus-Like Particle Vaccine Candidate Against Bluetongue Disease. [PDF]

Plant Biotechnol J
Mlingo TAM, O'Kennedy MM, Matsiela M, Nkomo N, Coetzee P, Rametse T, Mutowembwa P, Heath L, Mokoena N.   +8 more
europepmc   +1 more source

Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats. [PDF]

Vaccines (Basel)
Wang T, Wu H, Wang Y, Guan Y, Cao Y, Wang L, Wang M, Tan F, Pang W, Tian K.   +9 more
europepmc   +1 more source

Immunogenicity analyses and indirect ELISA application of a chimeric virus-like particle presenting a highly conserved peptide of Akabane virus Gc protein. [PDF]

Virol J
Wang J, Wei F, Yu R, Chen D, Wu S.
europepmc   +1 more source

FAME-CRISPR improves CRISPR-Cas9 genome editing via HDAC inhibition and engineered virus-like particle delivery. [PDF]

Cell Rep Methods
Djamshidi M, Hill A, Heshmatzad K, Langley J, Krowicki H, Ali M, Yang Y, Tanida R, Abdul-Careem MF, Billon P, Riabowol K.   +10 more
europepmc   +1 more source

Inhibitory Effect of <i>Curcuma xanthorrhiza</i> Extract Against SARS-CoV-2 D614G Virus-Like Particle (VLP): Implications for COVID-19 Therapy Development. [PDF]

ScientificWorldJournal
Mushlih M, Bemova M, Marzouk HA, Kusuma KH, Rohmah IN, Fitriana N, Prima A, Christina YI, Dwijayanti DR, Mustikaningtyas D, Widodo N, Djati MS, Widyarti S, Rifa'i M.   +13 more
europepmc   +1 more source

The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine. [PDF]

NPJ Vaccines
Crawford MW, Abdelwahab WM, Siram K, Parkins CJ, Harrison HF, Stone ET, Osman SR, Schweitzer D, Burkhart DJ, Pinto AK, Brien JD, Smith JL, Hirsch AJ.   +12 more
europepmc   +1 more source

Overcoming dengue vaccine challenges through next-generation virus-like particle immunization strategies. [PDF]

Front Cell Infect Microbiol
Parra-González M, Nájera-Maldonado L, Peralta-Cuevas E, Gutierrez-Onofre AJ, Garcia-Atutxa I, Villanueva-Flores F.   +5 more
europepmc   +1 more source